For more than 20 years, the Clinique médicale l’Actuel, under the direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.
The Evolution of the Standards of Care: The Changing Face of HIV Treatment
with Dr. Anton Pozniak and Dr. Réjean Thomas
- Are clinical trials giving us enough evidence for guidelines in the real world?
- Is it possible to simplify HIV treatments?
- What is going to be the impact of the arrival of single-pill generics in the treatment of HIV?
This activity is supported by
an educational grant from:
In this program, Dr. Réjean Thomas sits down with Dr. Anton Pozniak from the Chelsea and Westminster Hospital in London, UK, to discuss the pertinence of guidelines based on studies with patient populations that might not be representative of real life, the possibility of simplifying HIV treatments and what is going to be the impact of the arrival of single-pill generic medications in the treatment of HIV.
Réjean Thomas, M.D., D.H.C.
CEO | Founder
Clinique médicale l’Actuel:
Centre of Excellence HIV – STIs – Hepatitis
Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM)
Anton Pozniak, M.B., Ch.B., M.D., FRCP
Director of HIV services
Chelsea and Westminster Hospital
You must be logged in to view the complete program
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Réjean Thomas, MD, DHC, has a financial interest/relationship or affiliation in the form of:
Advisory: AbbVie, Bristol-Myers Squibb Janssen, Gilead, Merck, ViiV Healthcare.
Anton Pozniak, MB, ChB, MD, FRCP, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau, Faculty, Peer Reviewer, Advisory committee/board: AbbVie, Bristol-Myers Squibb, Janssen, Gilead, Merck, ViiV Healthcare.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.